BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

Lecanemab, which has been shown to target and remove beta-amyloid plaques, has been approved by the U.S. Food and Drug Administration to treat AD early in the disease's progression.

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42 ...

Alzheimer's disease is likely caused by stalled protein processing in the brain, according to a new study.

New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting brain protein amounts may offer cognitive benefits.

As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association ...

Lecanemab, which binds with high affinity to soluble amyloid-beta protofibrils, was approved to treat early Alzheimer's disease based on findings from the phase III CLARITY AD randomized trial.

“There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

These results – from no tau/low tau and low amyloid populations – suggest that earlier initiation of lecanemab treatment may have a positive impact on disease progression of early Alzheimer ...